P2X7 RECEPTOR ANTAGONISTS MARKET ANALYSIS

P2X7 Receptor Antagonists Market, by Drugs (AKP-23494954/RQ-00466479, EVT 401, GSK1482160, JNJ-55308942, JNJ-54175446, and Others (e.g.- AZ11657312)), by Application (Central Nervous System Disorders, Immunological Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published In : May 2019
Code : CMI2595
Pages :94
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Market Trends

Currently, there is no P2X7 receptor antagonist available in the market, and not a single P2X7 receptor antagonist in late stages of clinical trials. Therefore, manufacturers are competing on the same level with respect to the P2X7 receptor antagonist development. The category has a lucrative opportunity if a drug is introduced into the market, provided a drug successfully completes clinical trials. First mover to complete clinical trials, (and first to launch) will be able to gain significant share in the market, as healthcare systems always demand new medicines. Currently, opioid medications are heavily used for pain management and are highly addictive. Therefore, approval and launch of a non-addictive pain management option is expected to be a breakthrough in this product space.

However, leading international manufacturers such as GlaxoSmithKline Plc. and AstraZeneca Plc. have not been actively pursuing the advancement of P2X7 receptor antagonist category. For instance, GlaxoSmithKline Plc’s P2X7 candidate GSK1482160 is still in Phase 1 clinical trials and the study ended in April 2009. Moreover, the category has less number of candidates in the pipeline as compared to other conditions such as cancer and others. This factor has affected global P2X7 receptor antagonist market growth.